New York State Common Retirement Fund Boosts Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

New York State Common Retirement Fund lifted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 14.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 260,366 shares of the company's stock after purchasing an additional 32,015 shares during the quarter. New York State Common Retirement Fund owned 0.53% of Mirum Pharmaceuticals worth $11,729,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its position in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after buying an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $35,000. GF Fund Management CO. LTD. purchased a new position in Mirum Pharmaceuticals in the fourth quarter worth about $42,000. AlphaQuest LLC grew its holdings in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after purchasing an additional 1,658 shares during the last quarter. Finally, KBC Group NV acquired a new position in shares of Mirum Pharmaceuticals during the 1st quarter worth about $89,000.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 564 shares of the company's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $48.25, for a total value of $27,213.00. Following the completion of the transaction, the senior vice president owned 2,903 shares in the company, valued at $140,069.75. This represents a 16.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 22.87% of the company's stock.

Wall Street Analysts Forecast Growth

MIRM has been the subject of several analyst reports. Evercore ISI reissued an "outperform" rating on shares of Mirum Pharmaceuticals in a report on Friday, July 11th. HC Wainwright restated a "buy" rating and issued a $73.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, May 19th. Raymond James Financial reiterated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. JMP Securities boosted their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a report on Friday, May 9th. Finally, Wall Street Zen downgraded Mirum Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $65.50.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM traded up $0.02 during midday trading on Monday, reaching $51.95. The company's stock had a trading volume of 267,200 shares, compared to its average volume of 448,481. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.20 and a fifty-two week high of $54.78. The company has a market capitalization of $2.57 billion, a P/E ratio of -32.27 and a beta of 0.97. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.22 and a quick ratio of 3.04. The business's fifty day simple moving average is $48.30 and its 200-day simple moving average is $46.29.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. The business had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. During the same quarter last year, the firm earned ($0.54) EPS. The business's revenue was up 61.2% compared to the same quarter last year. As a group, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.